Elizabeth Holmes sharpens defense on second day of testimony

[ad_1]

But experts argued she had no choice but to defend herself, given the evidence presented by prosecutors. This included text messages showing Ms Holmes was aware of Theranoss’ technological issues and testimony about bogus demonstrations of his abilities. Prosecutors also revealed that after an employee, Erika Cheung, spoke to regulators about the problems in Theranos’ lab, the start-up hired a private investigator to follow her.

They think they’re late, and they have a smart, likable, young and attractive witness Neama Rahmani, chair of the West Coast trial lawyers and former federal prosecutor, said of Ms Holmes. And she thinks she’ll be okay with it.

A key point raised by prosecutors was that Theranos could never perform more than 12 different blood tests on its own machines. He secretly used blood analysis machines from companies like Siemens to perform most of his tests, but claimed he could do hundreds or thousands of them at different times.

Ms Holmess’ attorneys have tried for weeks to complicate the prosecution narrative. They pointed to the patents created by Theranos. They hammered investors for not doing enough due diligence on the start-up before eagerly writing checks to fund it. And they described Ms Holmes as inexperienced and unqualified to run a lab, blaming Theranoss’ failure on those who were experienced and skilled.

But at the helm, Ms. Holmes presented herself as an impressive and ambitious CEO in describing Theranos’ early days. She detailed a patent that bore her name for an early concept of the business, as well as the help she got from Channing Robertson, a respected scientist and professor at Stanford University who joined the board of administration of Theranoss. She was relaxed and confident, smiled widely and nodded before answering questions.

On Monday, his direct review continued in chronological order. Its attorneys reviewed the details of preliminary studies that Theranos had conducted with a number of pharmaceutical companies in 2008, 2009 and 2010. They also noted that Theranoss technology performed well in these early studies with Merck, AstraZeneca. , Centocor, Bristol Myers Squibb et al.

Representatives from Pfizer and Schering-Plow testified earlier that they had evaluated the Theranoss technology and were not impressed.

[ad_2]